Literature DB >> 1232004

Radioimmunoassay of norethindrone (17 alpha-ethynyl-17 beta-hydroxy-4-estren-3-one) and ethynyl-estradiol (17 alpha-ethynyl-1,3,5, (10)-estratien-3, 17 beta-diol). Application to human plasma determination of norethindrone after oral administration of this steroid.

J R Pasqualini, R Castellet, M C Portois, J L Hill, F A Kincl, J Cortes-Prieto.   

Abstract

The experiment conditions for the evaluation of Norethindrone (17 alpha-Ethynyl-17 beta-hydroxy-4-estren-3-one, NET) and Ethynyl-estradiol (17 alpha-ethynyl-1, 3, 5 (10) estratrien-3, 17 beta-diol, EE) by radioimmunoassay are described. A minimal quantity of 25 pg of these two steroids could be evaluated using different reduced metabolites of NET, very little cross reaction is observed with 200 pg of these metabolites. No effect was observed with estradiol for the EE-antiserum. The NET-antiserum was used to evaluate this steroid and ethynodiol diacetate after oral administration to female volunteers. Maximal values in the plasma (2-3% of the administered dose) was found between 1-3 h after administration and at 24 h a concentration of 0.1-0.3% still remained in the plasma.

Entities:  

Keywords:  Clinical Research; Contraception; Contraceptive Agents, Estrogen--analysis; Contraceptive Agents, Female--analysis; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--analysis; Ethinyl Estradiol--analysis; Ethynodiol Diacetate--analysis; Examinations And Diagnoses; Family Planning; Human Volunteers; Laboratory Examinations And Diagnoses; Laboratory Procedures; Norethindrone--analysis; Research Methodology

Mesh:

Substances:

Year:  1975        PMID: 1232004

Source DB:  PubMed          Journal:  Reproduccion        ISSN: 0303-5220


  2 in total

Review 1.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

2.  Bioavailability of norethindrone in human subjects.

Authors:  R A Okerholm; F E Peterson; F J Keeley; T C Smith; A J Glazko
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.